US20010051824A1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cardiac valve replacement
Assignee: Rhode Island Hospital
•
Filing: 2001-04-09
•
Granted: —
•
Expires: 2021-04-09
Abstract
Abstract The invention provides a replacement heart valve which contains an acellular matrix as a structural scaffold. The scaffold is seeded with isolated myofibroblasts and/or endothelial cells prior to implantation into a recipient mammal.
Inventors
- 👤 Richard Hopkins
- 👤 Diane Hoffman-Kim
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 04:10
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/38; A61L27/3804; A61L27/3839; A61L27/3843; A61L27/3895; A61L27/50; A61L27/507; A61F; A61F2/00; A61F2/02; A61F2/24; A61F2/2412; A61F2/2415; A61L2430/00; A61L2430/20
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
29 words
1 . A bioprosthetic heart valve comprising an acellular matrix and isolated myofibroblasts wherein at least 60% of the total collagen produced by said myofibroblasts is type I collagen.
Claim 2
Dependent Claim
29 words
1 . A bioprosthetic heart valve comprising an acellular matrix and isolated myofibroblasts wherein at least 60% of the total collagen produced by said myofibroblasts is type I collagen.
Claim 3
Dependent Claim
24 words
2 . The valve of claim 1 , wherein said myofibroblasts produce at least 2-fold greater type I collagen compared to type III collagen.
Claim 4
Dependent Claim
28 words
3 . The valve of claim 1 , wherein said myofibroblasts produce one or more extracellular matrix components selected from the group consisting of fibronectin, elastin, and glycosaminoglycan.
Claim 5
Dependent Claim
17 words
4 . The valve of claim 3 , wherein said glycosaminoglycan is chondroitin sulfate or hyaluronic acid.
Claim 6
Dependent Claim
27 words
5 . A valve comprising an acellular matrix and an isolated myofibroblast, wherein less than 25% of total collagen production by said myofibroblast is type III collagen.
Claim 7
Dependent Claim
27 words
5 . A valve comprising an acellular matrix and an isolated myofibroblast, wherein less than 25% of total collagen production by said myofibroblast is type III collagen.
Claim 8
Dependent Claim
23 words
6 . The valve of claim 5 , wherein less than 20% of total collagen production by said myofibroblast is type III collagen.
Claim 9
Dependent Claim
23 words
7 . The valve of claim 5 , wherein less than 15% of total collagen production by said myofibroblast is type III collagen.
Claim 10
Dependent Claim
19 words
8 . The valve of claim 5 , wherein said myofibroblast is derived from mammalian heart leaflet interstitial tissue.
Claim 11
Dependent Claim
20 words
9 . The valve of claim 5 , wherein said myofibroblast is derived from a mammalian vascular or dermal tissue.
Claim 12
Dependent Claim
19 words
10 . The valve of claim 5 , wherein said myofibroblast is derived from human heart leaflet interstitial tissue.
Claim 13
Dependent Claim
23 words
11 . A method of enhancing production of type I collagen by an isolated myofibroblast, comprising culturing said myofibroblast under pulsatile flow conditions.
Claim 14
Dependent Claim
23 words
11 . A method of enhancing production of type I collagen by an isolated myofibroblast, comprising culturing said myofibroblast under pulsatile flow conditions.
Claim 15
Dependent Claim
21 words
12 . The method of claim 11 , wherein said myofibroblast is cultured in the presence of basic fibroblast growth factor.
Claim 16
Dependent Claim
17 words
13 . The method of claim 11 , wherein said myofibroblast is cultured in endothelial cell-conditioned media.
Claim 17
Dependent Claim
21 words
14 . The method of claim 11 , wherein said myofibrobast is cultured in the presence of an isolated endothelial cell.
Claim 18
Dependent Claim
22 words
15 . A method of enhancing viability and contractile activity of myofibroblasts in vitro comprising culturing said myofibroblast under pulsatile flow conditions.
Claim 19
Dependent Claim
22 words
15 . A method of enhancing viability and contractile activity of myofibroblasts in vitro comprising culturing said myofibroblast under pulsatile flow conditions.
Claim 20
Dependent Claim
17 words
16 . The method of claim 15 , wherein said myofibroblast is cultured in endothelial cell-conditioned media.
Claim 21
Dependent Claim
21 words
17 . The method of claim 15 , wherein said myofibrobast is cultured in the presence of an isolated endothelial cell.
Claim 22
Dependent Claim
32 words
18 . The method of claim 15 , wherein said myofibroblast is cultured in the presence of a purified endothelial cell-derived growth factor, wherein said growth factor inhibits apoptosis of said myofibroblast.
Claim 23
Dependent Claim
23 words
19 . An isolated myofibroblast, wherein said myofibroblast is genetically altered to increase type I collagen production relative to type III collagen production.
Claim 24
Dependent Claim
23 words
19 . An isolated myofibroblast, wherein said myofibroblast is genetically altered to increase type I collagen production relative to type III collagen production.
Claim 25
Dependent Claim
13 words
20 . A bioprosthetic heart valve comprising the myofibroblast of claim 19 .
Claim 26
Dependent Claim
32 words
21 . A method of manufacturing an artificial heart valve, comprising (a) providing an acellular matrix, (b) seeding said matrix with isolated myofibroblasts; and (c) culturing said myofibroblasts under pulsatile flow conditions.
Claim 27
Dependent Claim
32 words
21 . A method of manufacturing an artificial heart valve, comprising (a) providing an acellular matrix, (b) seeding said matrix with isolated myofibroblasts; and (c) culturing said myofibroblasts under pulsatile flow conditions.
Claim 28
Dependent Claim
26 words
22 . The method of claim 21 , wherein said myofibroblasts are derived from an intended recipient from an intended recipient of said centrifugal heart valve.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.